Clinical Trials Browser

INDUSTRY × Has results × tucatinib × Clear all

NCT04430738 2026-02-24

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Phase 2 Active not recruiting

40 enrolled 67 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT04721977 2026-01-09

MK-7119-001

Phase 2 Active not recruiting

66 enrolled 7 charts

Breast Neoplasms

NCT03975647 2025-12-10

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Phase 3 Active not recruiting

466 enrolled 17 charts

HER2-positive Breast Cancer

NCT04539938 2025-09-30

HER2CLIMB-04

Phase 2 Completed

70 enrolled 11 charts

Breast Neoplasms

NCT04499924 2025-01-22

MOUNTAINEER-02

Phase 2/3 Completed

17 enrolled 23 charts

Gastrointestinal

Adenocarcinoma Of Esophagus

NCT03043313 2024-11-26

Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer

Phase 2 Completed

117 enrolled 21 charts 1 FDA

Gastrointestinal

Colorectal Neoplasms

NCT02614794 2023-08-14

HER2CLIMB

Phase 2 Completed

612 enrolled 30 charts 2 FDA

Brain Neoplasms, Breast Neoplasms

NCT05091528 2022-08-18

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

Phase 1/2 Terminated

2 enrolled 9 charts

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Colorectal Neoplasms